Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations

J Invest Dermatol. 2021 Apr;141(4):933-936.e6. doi: 10.1016/j.jid.2020.08.015. Epub 2020 Sep 14.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Alopecia Areata / diagnosis
  • Alopecia Areata / drug therapy*
  • Alopecia Areata / immunology
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Interleukin-2 / administration & dosage*
  • Interleukin-2 / adverse effects
  • Killer Cells, Natural / drug effects*
  • Killer Cells, Natural / immunology
  • Male
  • Middle Aged
  • Placebos / administration & dosage
  • Placebos / adverse effects
  • Prospective Studies
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Severity of Illness Index
  • T-Lymphocytes, Regulatory / drug effects*
  • T-Lymphocytes, Regulatory / immunology
  • Treatment Outcome
  • Young Adult

Substances

  • IL2 protein, human
  • Interleukin-2
  • Placebos
  • Recombinant Proteins